Fosun International Ltd - Company Profile
Powered by 
All the sales intelligence you need on Fosun International Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Fosun International Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Fosun International Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Fosun International Ltd (Fosun) is a global innovation-driven consumer group engaged in the operation and investment across sectors such as health, happiness, wealth, and intelligent manufacturing. The company offers a diverse range of products and services, including pharmaceutical and health products, medical services, tourism and leisure operations, fashion consumer goods, insurance services, asset management, and intelligent manufacturing. Fosun serves families worldwide, aiming to meet their needs in health, happiness, and wealth through its various business units. The company's products and services are utilized across industries such as healthcare, tourism, fashion, and financial services. Fosun operates through a network of business units and subsidiaries, although specific channel partners or distribution networks are not detailed. The company has a presence in multiple countries and regions, with target markets including China, Hong Kong, the UK, the US, and Portugal. Fosun is headquartered in Hong Kong, China.
Headquarters
Hong Kong
Address
Room 808, ICBC Tower, 3 Garden Road, Hong Kong City, 999077
Website
www.fosun.com
Telephone
852 2846 9888
No of Employees
103,900
Industry
Financial Services
Ticker Symbol & Exchange
656 (HKG)
Revenue (2024)
$24.1B
-9.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-438%
(2024 vs 2023)
Market Cap*
$4.0B
Net Profit Margin (2024)
XYZ
-496.9%
(2024 vs 2023)
* As of and is in US$
Fosun International Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Non-life Insurance | Healthcare Services | Fosun |
| Life and Non-life Reinsurance | Secondary Market Investments | |
| Medical and Pharmaceutical Products | Venture Capital and Private Equity Investments | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In December, Fosun Pharma's Chongqing Yaoyou Pharmaceutical Co., Ltd. and Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. entered into an agreement with Pfizer Inc. to grant Pfizer rights to develop, use, manufacture, and commercialize its oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist (including YP05002). |
| 2025 | Divestiture | In July, Bridge Fortune Investment divested Hauck Aufhauser Lampe Private Bank to ABN AMRO, a private banking company. |
| 2025 | Contracts/Agreements | In February, the company signed a partnership with Abu Dhabi Investment Office to support the expansion of Fosun’s subsidiaries into Abu Dhabi and the Middle East. |
Competitor Comparison
| Key Parameters | Fosun International Ltd | Ping An Insurance (Group) Company of China Ltd | China Pacific Insurance (Group) Co Ltd | Huatai Insurance Group Co Ltd | China National Pharmaceutical Group Corp |
|---|---|---|---|---|---|
| Headquarters | Hong Kong | China | China | China | China |
| City | Hong Kong City | Shenzhen | Shanghai | Beijing | Beijing |
| State/Province | - | Guangdong | Shanghai | Beijing | Beijing |
| No. of Employees | 103,900 | 258,806 | 91,639 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Guo Guangchang | Chairman | Executive Board | - | 58 |
| Gong Ping | Director; Chief Financial Officer; President | Executive Board | 2021 | 50 |
| Pan Donghui | Chief Human Resource Officer; President; Director | Executive Board | 2023 | 56 |
| Huang Zhen | Director; President; Chief Growth Officer | Executive Board | 2022 | 54 |
| Chen Qiyu | Co- Chief Executive Officer; Director | Executive Board | - | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer